Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting a phase III clinical trial to evaluate the protective effects, safety, and immune response of a recombinant respiratory syncytial virus RSV vaccine made with CHO cells. The study involves adults aged 60 years and older, including about 30% aged 70 and above, with a balanced mix of men and women. Participants are randomly assigned to receive either the vaccine or a placebo, and the trial aims to assess the vaccines ability to prevent lower respiratory tract disease caused by RSV. Participants will receive one dose of either the investigational vaccine or a placebo injection on Day 0. The vaccine dose involves mixing an antigen powder with an adjuvant liquid before intramuscular injection into the upper arm. The placebo consists of a sodium chloride solution administered similarly. A subset of 1,200 participants will have their immune response closely studied. The trials evaluation period can last up to 12 months following vaccination. During the study, participants will be monitored for respiratory illnesses, including lower respiratory tract disease and acute respiratory infections, with assessments starting 14 days after vaccination and continuing for up to a year. Safety will be carefully tracked through reports of adverse events within days to a year after vaccination. The study includes scheduled follow-ups to collect data on vaccine effectiveness and immune response. Participation may last up to 12 months from the vaccination date.